Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
10:31am, Wednesday, 04'th Feb 2026
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
10:20am, Wednesday, 04'th Feb 2026
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Novo Nordisk files annual report with the SEC
09:53am, Wednesday, 04'th Feb 2026
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating b
Novo Nordisk risks weight-loss price war as discount pressures deepen
09:33am, Wednesday, 04'th Feb 2026
Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" price pressure forces it to slash the cost of its blockbuster Wegovy drug in
Novo Nordisk: Pfizer weight loss drug offers credible new competition
08:45am, Wednesday, 04'th Feb 2026
Pfizer's monthly GLP-1 data prompts caution as new rival approaches Phase III Citi has reiterated its 'neutral' stance on Novo Nordisk (NYSE:NVO), warning that competition in the obesity drug market c
Novo Nordisk plunge wipes $50 billion off obesity drug giant
08:21am, Wednesday, 04'th Feb 2026
Novo Nordisk shares tumbled 16% on Wednesday, wiping off around $50 billion from the Wegovy maker's market capitalization after it warned on Tuesday its sales and profits would fall in 2026.
Novo Nordisk Warns Sales Could Fall Up to 13%, Shares Drop 20%
07:54am, Wednesday, 04'th Feb 2026
Shares of Novo Nordisk (NVO) fell sharply after the company delivered a surprisingly downbeat sales outlook, warning that revenue could decline by as much as 13
$285 Billion AI-Led Selloff Triggers Rotation Into Small Caps
07:44am, Wednesday, 04'th Feb 2026
Renewed volatility linked to artificial-intelligence disruption has prompted a sharp shift in investor positioning, following a roughly $285 billion global sell
First Look: Lilly jumps; Novo warns; Walmart tops $1T
07:38am, Wednesday, 04'th Feb 2026
Stock News Lilly beats and lifts outlook: Eli Lilly (LLY) posted Q4 revenue of $19.29B (+43%) and adjusted EPS of $7.54, and guided 2026 revenue to $80â$83B a
Novo Nordisk Faces Massive Sell-Off After Weak 2026 Outlook
06:12am, Wednesday, 04'th Feb 2026
Novo Nordisk (NVO) shares slid about 14% on Tuesday after trading resumed from a brief halt, following the drugmaker's release of mixed results for 2025 and a c
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
05:41am, Wednesday, 04'th Feb 2026
Having pre-announced earnings a day earlier, Novo Nordisk CEO Mike Doustdar, faced the European media Wednesday morning and gave a series of downbeat assessments of the company's prospects in 2026.
Novo CEO defends guidance as stock slides
04:38am, Wednesday, 04'th Feb 2026
Novo Nordisk CEO Mike Doustdar warns things will get worse before they get better for the obesity drugmaker after it issued disappointing guidance, causing its stock to tumble. 🔗Read more: cnb.cx/3
Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints
03:47am, Wednesday, 04'th Feb 2026
The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
03:08am, Wednesday, 04'th Feb 2026
"People should expect that it goes down before it comes back up," CEO Mike Doustdar told CNBC's "Early Edition Europe" on Wednesday. In this article NVO
Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future
03:06am, Wednesday, 04'th Feb 2026
Novo Nordisk CEO Mike Doustdar said on Wednesday that the price reductions for its obesity drug Wegovy in the U.S. are "painful" for the company's financial results but he hopes that they will be an i
